ArticleScientific reports2025
Prognostic implications of complement C1q-like 4 expression in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [MBD1 knockdown inhibits proliferation, migration and angiogenesis of human umbilical vein endothelial cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- The serum C1q-to-CRP ratio performs well for diagnosing periprosthetic joint infection in revision arthroplasty.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Higher expression of Complement C1q-like protein 4 (C1ql4) in breast cancer may be associated with increased tumor malignancy. As a protein involved in immune responses and inflammation, C1ql4 is expressed across all molecular subtypes of breast cancer. We conducted a retrospective analysis and follow-up study involving 111 patients who underwent breast cancer resection at the Department of Breast Surgery, Affiliated Hospital of Chengde Medical College, to investigate the relationship between C1ql4 expression and overall survival, as well as to evaluate the prognostic value of C1ql4 both independently and in combination with conventional clinicopathologic parameters. Chi-square analysis revealed a significant positive difference between C1ql4 protein expression and TNM staging, as well as molecular subtypes. Moreover, patients with high C1ql4 expression demonstrated significantly poorer prognoses. In conclusion, our findings suggest that C1ql4 expression may serve as a potential biomarker for elevated breast cancer malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.